Form 4/A for URGN UroGen Pharma Ltd.
Accepted 2023-02-28 00:00:00 ET · period of report 2022-06-06 · accession 0001437749-23-004870 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DAI | 2023-02-28 | 2022-06-06 | URGN | Nussbaum Ran | Dir | M - OptEx | $5.00 | +1,030 | 1.43M | +0.1% | +$5,150 |
| DAI | 2023-02-28 | 2022-06-06 | URGN | Nussbaum Ran | Dir | M - OptEx | $0.00 | -1,030 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-06-06 | M | A | 1,030 | $5.00 | 1,434,958 | I Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd. | — | — | (F1) On August 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,433,928 shares of securities beneficially owned following reported transaction instead of 1,434,958 shares. |
| 2 | Derivative | Stock Option (right to buy) | 2022-06-06 | M | D | 1,030 | $0.00 | 0 | I By Pontifax Cayman III Limited Partnership | $5.00 · 2015-09-01 to 2022-09-01 | 1,030 Ordinary Shares | (F2) On August 25, 2022, the reporting person filed a Form 4 that inadvertently list the expiration date as August 31, 2022. |